Abstract

Introduction:This article aims at investigating the 5-year budget impact of rituximab biosimilars in Italy.Methods:A budget impact analysis model was developed in accordance with the International ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran.
Meysam Seyedifar ... Menhajuddin Sabouri
Medicine | VOL. 102
Meysam Seyedifar, et. al.Meysam Seyedifar ... Menhajuddin Sabouri
01 Sep 2023
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina.
Carlos Rojas-Roque ... Fernando Argento
PharmacoEconomics - open | VOL. -
Carlos Rojas-Roque, et. al.Carlos Rojas-Roque ... Fernando Argento
03 Jun 2024
Practical issues in handling data input and uncertainty in a budget impact analysis
M J C Nuijten ... T Mittendorf
The European journal of health economics : HEPAC : health economics in prevention and care | VOL. 12
M J C Nuijten, et. al.M J C Nuijten ... T Mittendorf
03 Apr 2010
Budget impact analysis of an early identification and referral model for diagnosing patients with suspected rheumatoid arthritis in Ireland.
Dan Kelleher ... Bernie Mcgowan
Rheumatology advances in practice | VOL. 4
Dan Kelleher, et. al.Dan Kelleher ... Bernie Mcgowan
01 Jul 2020
View more papers

More From: Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish

Paper Title
Journal
Date
Author
Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses
Nicola Amedeo Mazzanti ... Carolina Scauri
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish | VOL. 2019
Nicola Amedeo Mazzanti, et. al.Nicola Amedeo Mazzanti ... Carolina Scauri
01 Jan 2019
The economic impact of biosimilars in Italy: a scenario analysis
Francesco S Mennini ... Andrea Marcellusi
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish | VOL. 2019
Francesco S Mennini, et. al.Francesco S Mennini ... Andrea Marcellusi
01 Jan 2019
Twenty Years of Hepatitis C in the Treviso District (Local Health Unit 2): Treatments, Clinical Management and Cost Analysis
Annachiara Bellin ... Alessandra Bettiol
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish | VOL. 2019
Annachiara Bellin, et. al.Annachiara Bellin ... Alessandra Bettiol
01 Jan 2019
Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
Ravasio R ... Coffani M
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish | VOL. 2019
Ravasio R, et. al.Ravasio R ... Coffani M
01 Jan 2019
View more papers